Roche this week announced the launch of the xCELLigence system, a cell-based assay system that integrates microelectronics and cell biology.
xCELLigence was originally invented by Acea Biosciences, and co-developed by Roche and Acea. The xCELLigence system will be marketed exclusively by Roche on a worldwide basis.
The xCELLigence System comprises four main components: the RTCA Analyzer, the RTCA SP Station, the RTCA Computer and integrated Software, and the disposable 96-well microtiter E-Plate. The RTCA SP Station is located inside a standard tissue culture incubator and can switch any one of the wells on the E-Plate 96 to the RTCA Analyzer for impedance measurement.
The RTCA SP Analyzer automatically selects wells for measurement and continuously transfers measured impedance data to the computer. Cell index values, derived from the measured impedances, are continuously displayed in real time by the software user interface.
A microelectronic biosensor is built into each well of the standard 16- or 96-well E Plate microtiter plates. A cell in contact with the sensor changes the electrical impedance between the microelectrodes.
Each change in the cell’s status — for example, changes in cell adhesion, cytotoxicity, cell proliferation, cell–cell interactions, and morphological changes — leads to changes in the impedance measurements, and can be detected in real time. Labeling of the cells, which can induce non-physiological changes in the cells, is not necessary.
This technology is appropriate for uninterrupted monitoring of processes in living cells and for monitoring real-time kinetics, the company said.